Research programme: PKR/PKRM2 modulators - Agios Pharmaceuticals
Latest Information Update: 16 Mar 2023
At a glance
- Originator Agios Pharmaceuticals
- Class
- Mechanism of Action Pyruvate kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 16 Mar 2023 Research programme: PKR/PKRM2 modulators - Agios Pharmaceuticals is available for licensing as of 16 Mar 2023. https://www.agios.com/patients-partners/partner-opportunities/
- 09 Mar 2023 Preclinical trials in Unspecified in USA (unspecified route) (Agios Pharmaceuticals pipeline, March 2023).)